Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Replacement therapy for congenital Factor X deficiency.

R D Knight, C F Barr, B M Alving

    Transfusion
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

    Leukemia·2015
    Same author

    Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

    Leukemia·2013
    Same author

    Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

    Leukemia·2009
    Same author

    Re: Noise levels generated within the external auditory canal during microsuction aural toilet and the effect on hearing: a prospective controlled series.

    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2009
    Same author

    Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004.

    Transfusion medicine (Oxford, England)·2007
    Same author

    Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.

    European journal of cancer (Oxford, England : 1990)·2006
    Same journal

    Identifying blood deserts in Liberia: A geospatial analysis.

    Transfusion·2026
    Same journal

    Clot contraction of whole blood diminishes during storage and can be restored by adding platelets.

    Transfusion·2026
    Same journal

    Investigation of the preanalytical stability of blood donor samples.

    Transfusion·2026
    Same journal

    The need for dried plasma-Still a national issue: Where are we and recommendations.

    Transfusion·2026
    Same journal

    Spray dried plasma manufactured from apheresis and whole blood derived plasma.

    Transfusion·2026
    Same journal

    Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

    Transfusion·2026
    See all related articles

    This study shows that maintaining factor X levels between 10-20% is sufficient for hemostasis in patients with severe congenital factor X deficiency, even after surgery. This finding is crucial for managing bleeding risks in these patients.

    Area of Science:

    • Hematology
    • Coagulation Disorders

    Background:

    • Congenital factor X deficiency is a rare bleeding disorder.
    • Determining optimal factor replacement levels for hemostasis is critical.

    Observation:

    • A young woman with severe (less than 1%) congenital factor X deficiency was studied over two years.
    • Factor X levels were monitored during various bleeding events and surgical procedures.

    Findings:

    • Levels of 9-17% factor X, achieved with fresh-frozen plasma (FFP), were adequate for minor bleeding (vaginal bleeding, epistaxis, hemarthroses).
    • Emergency surgery for hemoperitoneum required a factor X level of 35%, achieved with Factor IX concentrate, followed by FFP infusions to maintain 10-20% postoperatively for 6 days.

    Implications:

    Related Experiment Videos

  • Factor X levels of 10-20% appear sufficient for hemostasis in factor X-deficient patients, including the immediate postoperative period.
  • These findings provide valuable guidance for managing bleeding in congenital factor X deficiency.